What Phase 3 Means: Understanding the TRIUMPH Program

The Pivotal Moment

Retatrutide has entered Phase 3 clinical development, designated the TRIUMPH program. For those following this molecule’s progress, Phase 3 represents the most consequential stage of its development journey. But what exactly does Phase 3 mean, and what should we expect?

Phase 3: The Basics

Phase 3 trials are the large-scale, pivotal studies that provide the definitive evidence for or against a drug’s approval. If Phase 1 asks “is it safe enough to continue testing?” and Phase 2 asks “does it work and what’s the right dose?”, Phase 3 asks “does it work well enough and safely enough, in a large and diverse population, to justify approval?”

The key characteristics that distinguish Phase 3 from earlier phases:

Scale: Phase 2 studies typically enroll hundreds of participants. Phase 3 trials enroll thousands, sometimes tens of thousands. This larger scale serves two purposes: greater statistical power to confirm efficacy and a larger safety database to detect uncommon adverse events.

Diversity: Phase 3 trials are typically multinational, enrolling participants across many countries, ethnic groups, age ranges, and comorbidity profiles. This ensures the results are generalizable beyond the relatively homogeneous populations of earlier trials.

Duration: Phase 3 obesity trials typically last 68-72 weeks or longer, compared to the 48-week duration of retatrutide’s Phase 2. This longer treatment period captures the full trajectory of weight loss and provides more comprehensive safety data.

Rigor: While Phase 2 trials are rigorously designed, Phase 3 protocols are developed in close consultation with regulatory agencies and undergo even more intensive monitoring and auditing.

What TRIUMPH Is Designed to Answer

The TRIUMPH program (Triple Receptor Agonist Intervention Utilizing Metabolic Pathways in Health) includes at least two pivotal trials:

TRIUMPH-1: Obesity

The primary question: Does retatrutide produce clinically meaningful, statistically significant weight loss in a large, diverse population of adults with obesity?

Specific questions include:

• Is the ~22-24% weight loss from Phase 2 reproducible at scale?
• What is the weight loss at 68-72 weeks (longer than Phase 2’s 48 weeks)?
• What proportion of participants achieve the ≥5%, ≥10%, ≥15%, and ≥20% thresholds?
• Are the results consistent across demographic subgroups (age, sex, race, BMI category)?
• What is the comprehensive safety profile in a large population?

TRIUMPH-2: Obesity/Overweight With Type 2 Diabetes

The primary question: Does retatrutide produce clinically meaningful weight loss in adults with obesity or overweight (BMI ≥27) who also have type 2 diabetes?

TRIUMPH-2 includes a nested OSA basket evaluating changes in the apnea-hypopnea index. Doses are 4 mg, 9 mg, and 12 mg in approximately 1,000 participants. Specific questions include:

• Is the weight loss benefit meaningful in the diabetes population, where obesity pharmacotherapy typically shows attenuated results?
• Does weight loss translate into OSA improvement (AHI reduction) in the nested basket?
• What are the secondary glycemic effects (HbA1c, fasting glucose)?
• How does the safety profile compare to Phase 2, particularly regarding hypoglycemia?

What Success Looks Like

For the FDA to approve retatrutide for obesity, the trial needs to show:

• Statistically significant weight loss versus placebo
• At least 5% mean weight loss (retatrutide far exceeds this based on Phase 2)
• An acceptable safety profile where benefits clearly outweigh risks
• Consistent results across the pre-specified primary and key secondary endpoints

For type 2 diabetes approval:

• Statistically significant HbA1c reduction versus placebo
• Acceptable safety, including low hypoglycemia rates
• Favorable benefit-risk assessment

Based on the Phase 2 data, meeting the efficacy bar should be straightforward if results are even directionally consistent. The primary uncertainty is on the safety side: whether the larger Phase 3 database will reveal any uncommon adverse events not detected in Phase 2.

Common Misconceptions About Phase 3

”Phase 3 is just a formality after strong Phase 2 results”

This is incorrect. Approximately 50-60% of drugs that enter Phase 3 eventually receive FDA approval. The failure rate is significant because Phase 3 can reveal efficacy attenuation, unexpected safety signals, or manufacturing challenges that were not apparent in earlier phases.

”Phase 2 results predict Phase 3 results exactly”

Phase 3 effect sizes are often modestly smaller than Phase 2 for several reasons: larger and more diverse populations, more conservative trial designs, and the statistical phenomenon of regression to the mean. However, this is not always the case. TRIUMPH-4, the first Phase 3 readout (December 2025), actually exceeded Phase 2: the 12 mg group achieved 28.7% mean weight loss at 68 weeks in 445 participants with obesity and knee osteoarthritis, compared to 24.2% at 48 weeks in Phase 2. The longer treatment duration (68 vs. 48 weeks) and optimized five-step dose escalation protocol likely contributed. Phase 3 also revealed a new safety signal — dysesthesia in 20.9% of the 12 mg group — demonstrating that larger trials can uncover adverse events not prominent in earlier phases.

”Phase 3 results will be available quickly”

Phase 3 obesity trials take years from first enrollment to final data readout. The timeline includes enrollment (which can take 12-18 months for large global trials), treatment duration (68-72 weeks), data collection, analysis, and reporting. Patience is required.

What to Watch For

As TRIUMPH results emerge, focus on:

1. Primary endpoint: The mean weight loss (obesity) or HbA1c reduction (diabetes) versus placebo. This is the result that matters most for regulatory approval.

2. Responder rates: What proportion of participants achieved clinically meaningful thresholds? Consistent high response rates would confirm the Phase 2 pattern.

3. Safety database: The adverse event profile across thousands of participants, particularly any events not observed in Phase 2.

4. Discontinuation rates: What proportion of participants stopped treatment due to adverse events? If Phase 3 dose-escalation protocols improve on Phase 2 tolerability, this would be encouraging.

5. Subgroup analyses: Were the results consistent across age, sex, race, and baseline BMI? Inconsistencies could limit the drug’s applicability.

6. Weight trajectory: Did weight loss continue beyond the 48-week Phase 2 timepoint? If so, what was the maximum effect and when was it reached?

The Road Ahead

Phase 3 is the most resource-intensive and time-consuming phase of drug development. Eli Lilly is investing substantial resources in the TRIUMPH program, and the first readout has validated that investment. TRIUMPH-4 results, announced in December 2025, confirmed and exceeded Phase 2 efficacy expectations.

Six additional Phase 3 readouts are expected in 2026, and Eli Lilly has indicated plans to file a New Drug Application (NDA) in late 2026, placing potential FDA approval in the mid-2027 to early 2028 timeframe. For the scientific community and for patients, the remaining TRIUMPH readouts will fill in the picture across the core obesity and diabetes populations that form the basis of regulatory submissions.